Related Experiment Video
Updated: Oct 9, 2026

Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP
Published on: February 14, 2022
Aerosolized iloprost for severe pulmonary hypertension as a bridge to heart transplantation
T Wittwer1, K Pethig, M Strüber
1Department of Thoracic, Medical School Hannover, Germany. th.wittwer-md@t-online.de
Insights
Preexisting pulmonary hypertension poses risks for pediatric heart transplant recipients. Intensified prostacyclin and dobutamine pretreatment stabilized a patient, enabling successful cardiac transplantation without combined heart-lung procedures.
Area of Science:
- Cardiology
- Pulmonology
- Transplantation Medicine
Background:
- Pediatric patients with preexisting pulmonary hypertension face poor outcomes after cardiac transplantation.
- Donor right ventricular dysfunction is a significant contributing factor to adverse outcomes.
Observation:
- A 17-year-old patient with pulmonary hypertension required cardiac transplantation.
- Combined heart-lung transplantation was considered to manage the high pulmonary vascular resistance.
Findings:
- An intensified pretreatment regimen was administered, including intravenous prostacyclin and dobutamine.
- Inhalative therapy with the prostacyclin analog Iloprost was also used.
- This comprehensive approach led to hemodynamic stabilization of the patient.
Implications:
- The successful hemodynamic stabilization allowed for a 21-day waiting period for the cardiac transplant.
- An uneventful cardiac transplantation was subsequently performed, avoiding the need for combined heart-lung transplantation.
- This strategy offers a potential alternative for managing pediatric heart transplant candidates with severe pulmonary hypertension.
Abstract:
Preexisting pulmonary hypertension in pediatric patients is associated with poor outcome after cardiac transplantation because of donor right ventricular dysfunction. To avoid a combined heart-lung transplantation in a 17-year-old patient, we used an intensified pretreatment with intravenous prostacyclin and dobutamine combined with an inhalative therapy with the aerosolized prostacyclin-analog Iloprost. With this regimen, the patient was hemodynamically stabilized for the waiting period of 21 days after which an uneventful cardiac transplantation was performed.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
COPD: Management Using Bronchodilators and Corticosteroids
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

